McAdam LLC’s Axsome Therapeutics AXSM Stock Holding History

McAdam LLC’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$361K	Sell	2,135 -139	-6%	-$24K	0.02%	303
2025 Q4	$415K	Buy	2,274 +76	+3%	+$10.6K	0.02%	268
2025 Q3	$267K	Buy	2,198 +2	+0.1%	+$225	0.01%	330
2025 Q2	$229K	Buy	2,196 +2	+0.1%	+$212	0.01%	340
2025 Q1	$256K	Buy	+2,194	New	+$250K	0.02%	283
2020 Q1	–	Sell	-2,114	Closed	-$219K	–	109
2019 Q4	$219K	Buy	+2,114	New	+$85.4K	0.05%	81
2018 Q4	–	Sell	-2,000	Closed	-$7K	–	100
2018 Q3	$7K	Hold	2,000	–	–	﹤0.01%	373
2018 Q2	$6K	Buy	+2,000	New	+$6.2K	﹤0.01%	368

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

McAdam LLC's AXSM Position: Q1 2026 in Review

McAdam LLC reduced its Axsome Therapeutics (AXSM) stake by 6.1% in Q1 2026, selling an estimated $24K and leaving 2,135 shares worth $361K. The position accounts for 0.02% of the portfolio, ranked #303.

McAdam LLC first reported a position in AXSM in Q2 2018 and has held it in 8 quarters since. The position peaked at $415K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

McAdam LLC held 2,135 shares of Axsome Therapeutics worth $361K as of Q1 2026.
McAdam LLC sold 139 Axsome Therapeutics shares in Q1 2026, an estimated $24K.
Axsome Therapeutics made up 0.02% of McAdam LLC's portfolio in Q1 2026, its #303 holding.
McAdam LLC first reported a position in Axsome Therapeutics in Q2 2018 and has held it in 8 quarters since.
McAdam LLC's Axsome Therapeutics position peaked at $415K in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on McAdam LLC's 13F filing for Q1 2026, filed 8 May 2026.